Phase IAndrogen Modulator
Compound 61416
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061416
Risk Class
MODERATE
Last Audit
Jan 29, 2108
Research Abstract
Androgen Modulator candidate engineered for cognitive resilience initiatives with automated dossier coverage.
Compound 61416 is a androgen modulator asset inside androgen modulator innovation track initiatives, optimized for cognitive resilience and neuroprotection.
The dossier currently sits in phase i with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061416 with updates logged 2108-01-29.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Cognitive resilienceNeuroprotection
Nomenclature
CX-61416Androgen Modulator Program 61416
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061416
- [2] Operations Pulse • Androgen Modulator innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61416